These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 31020653)

  • 1. Outcomes of patients on dual antiplatelet therapy post-coronary stenting following emergency noncardiac surgery.
    Irie H; Kawai K; Otake T; Shinjo Y; Kuriyama A; Yamashita S
    Acta Anaesthesiol Scand; 2019 Sep; 63(8):982-992. PubMed ID: 31020653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting.
    Costa F; Van Klaveren D; Feres F; James S; Räber L; Pilgrim T; Hong MK; Kim HS; Colombo A; Steg PG; Bhatt DL; Stone GW; Windecker S; Steyerberg EW; Valgimigli M;
    J Am Coll Cardiol; 2019 Feb; 73(7):741-754. PubMed ID: 30784667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective observational cohort study of the association between antiplatelet therapy, bleeding and thrombosis in patients with coronary stents undergoing noncardiac surgery.
    Howell SJ; Hoeks SE; West RM; Wheatcroft SB; Hoeft A;
    Br J Anaesth; 2019 Feb; 122(2):170-179. PubMed ID: 30686302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perioperative major adverse cardiac events in urgent femoral artery repair after coronary stenting are less common than previously reported.
    Mujagic E; Zeindler J; Coslovsky M; Mueller C; du Fay de Lavallaz J; Jeger R; Kaiser C; Gurke L; Wolff T
    J Vasc Surg; 2019 Jul; 70(1):216-223. PubMed ID: 30922743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study.
    Secemsky EA; Yeh RW; Kereiakes DJ; Cutlip DE; Cohen DJ; Steg PG; Cannon CP; Apruzzese PK; D'Agostino RB; Massaro JM; Mauri L;
    JAMA Cardiol; 2017 May; 2(5):478-487. PubMed ID: 28297015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Efficacy of Extended Dual Antiplatelet Therapy After Left Main Coronary Artery Bifurcation Stenting.
    Cho S; Kim JS; Kang TS; Hong SJ; Shin DH; Ahn CM; Kim BK; Ko YG; Choi D; Song YB; Hahn JY; Choi SH; Gwon HC; Hong MK; Jang Y
    Am J Cardiol; 2020 Feb; 125(3):320-327. PubMed ID: 31780076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiplatelet therapy and outcome in patients undergoing surgery following coronary stenting: Results of the surgery after stenting registry.
    Rossini R; Angiolillo DJ; Musumeci G; Capodanno D; Lettino M; Trabattoni D; Pilleri A; Calabria P; Colombo P; Bernabò P; Ferlini M; Ferri M; Tarantini G; De Servi S; Savonitto S
    Catheter Cardiovasc Interv; 2017 Jan; 89(1):E13-E25. PubMed ID: 27404797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risks of noncardiac surgery after coronary stenting.
    Reddy PR; Vaitkus PT
    Am J Cardiol; 2005 Mar; 95(6):755-7. PubMed ID: 15757604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial.
    Costa F; Vranckx P; Leonardi S; Moscarella E; Ando G; Calabro P; Oreto G; Zijlstra F; Valgimigli M
    Eur Heart J; 2015 May; 36(20):1242-51. PubMed ID: 25718355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial.
    Collet JP; Silvain J; Barthélémy O; Rangé G; Cayla G; Van Belle E; Cuisset T; Elhadad S; Schiele F; Lhoest N; Ohlmann P; Carrié D; Rousseau H; Aubry P; Monségu J; Sabouret P; O'Connor SA; Abtan J; Kerneis M; Saint-Etienne C; Beygui F; Vicaut E; Montalescot G;
    Lancet; 2014 Nov; 384(9954):1577-85. PubMed ID: 25037988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit of Prolonged Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stent for Coronary Bifurcation Lesions: Results From the Coronary Bifurcation Stenting Registry II.
    Jang WJ; Ahn SG; Song YB; Choi SH; Chun WJ; Oh JH; Cho SW; Kim BS; Yoon JH; Koo BK; Yu CW; Jang YS; Tahk SJ; Kim HS; Gwon HC; Lee SY; Hahn JY
    Circ Cardiovasc Interv; 2018 Jul; 11(7):e005849. PubMed ID: 30006330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents.
    Hermiller JB; Krucoff MW; Kereiakes DJ; Windecker S; Steg PG; Yeh RW; Cohen DJ; Cutlip DE; Massaro JM; Hsieh WH; Mauri L;
    JACC Cardiovasc Interv; 2016 Jan; 9(2):138-47. PubMed ID: 26793956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Bittl JA; Baber U; Bradley SM; Wijeysundera DN
    J Am Coll Cardiol; 2016 Sep; 68(10):1116-39. PubMed ID: 27036919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Catastrophic outcomes of noncardiac surgery soon after coronary stenting.
    Kałuza GL; Joseph J; Lee JR; Raizner ME; Raizner AE
    J Am Coll Cardiol; 2000 Apr; 35(5):1288-94. PubMed ID: 10758971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
    Secemsky EA; Yeh RW; Kereiakes DJ; Cutlip DE; Steg PG; Massaro JM; Apruzzese PK; Mauri L;
    JACC Cardiovasc Interv; 2017 May; 10(9):942-954. PubMed ID: 28473118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual antiplatelet therapy with aspirin and clopidogrel: what is the risk in noncardiac surgery? A narrative review.
    Finkel JB; Marhefka GD; Weitz HH
    Hosp Pract (1995); 2013 Feb; 41(1):79-88. PubMed ID: 23466970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    ; Bittl JA; Baber U; Bradley SM; Wijeysundera DN
    Circulation; 2016 Sep; 134(10):e156-78. PubMed ID: 27026019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of dual antiplatelet therapy interruption within 1 year after primary percutaneous coronary intervention in patients with acute ST elevation myocardial infarction.
    Tam CC; Lee J; Chan KW; Lam CC; Wong YT; Chan E; Sze M; Lam YM; Chan C; Tse HF; Siu CW
    Postgrad Med J; 2020 Jan; 96(1131):9-13. PubMed ID: 31324730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation of antiplatelet therapy prior to low-risk noncardiac surgery in patients with drug-eluting stents: a retrospective cohort study.
    Brotman DJ; Bakhru M; Saber W; Aneja A; Bhatt DL; Tillan-Martinez K; Jaffer AK
    J Hosp Med; 2007 Nov; 2(6):378-84. PubMed ID: 18081175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents.
    Hawn MT; Graham LA; Richman JS; Itani KM; Henderson WG; Maddox TM
    JAMA; 2013 Oct; 310(14):1462-72. PubMed ID: 24101118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.